Prevalence of Second Primary Malignancies in Patients With Well-Differentiated Neuroendocrine Tumors
Authors' conclusion
The risk of SPMs is high in NETs, with multiple neoplasms diagnosed in over one sixth of patients. Active surveillance for SPMs is strongly indicated and should be integral to the follow-up of NETs.
Study context
- Population
- Patients with metastatic well-differentiated gastro-entero-pancreatic neuroendocrine tumors (NETs) and lung carcinoids treated with SSA at a specialized center
- Participants
- 135 vs 94
- Exposure
- NETs vs control group
- NETsn = 135
- Controln = 94reference
- Outcome
- Prevalence of second primary malignancies (SPMs)
Methodological detailssingle-centre, control group
- Single-centre
- Control group
Main finding
As reported in the abstract
SPMs
Control
7.7%
7
P = 0.029
- 26 Second Primary Malignancies (SPMs) diagnosed in 24 patients
- 17.8%
Observational data: associations, not effects.
Further findings
- Duration from NET diagnosis to end of follow-up — NETs
- mean 5.3 (SD 3.8) years
- Age at end of follow-up (NETs)
- 64.8 · mean · SD 10.2 · years
Original publication
Prevalence of Second Primary Malignancies in Patients With Well-Differentiated Neuroendocrine Tumors. Endocr Pract. Published 3 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →